The objective of this study was to evaluate the effects of magnesium hydroxide (MH) on disintegration time (DT) and dissolution profile of diclofenac sodium (DS) plain tablet. The tablets of DS were formulated with conventionally used excipients and investigational agent Mg [OH] 2 . Different parameters of tablets like hardness, thickness, friability, and disintegration time and dissolution rate were determined to assess the effects of MH on these parameters. The physical resistance against abrasion or shock of DS-MH tablets had been noticed by the results of hardness and friability test which were within the limits of standard specification. The disintegration times of tablets of the experimental batches except one, found 2.0 to 25 minutes were also within the limits of standard specification. The release rates of DS in simulated gastric fluid (SGF) at 30 minutes were inspiring about batches FO3: 84.78% and FO4: 90.38%. A positive correlation of coefficient determined between quantity of Mg(OH) 2 in different batches of tablets and their effects on dissolution rate was found statistically significant (r = 0.66). The t max of DS was not affected by the presence or increment of MH as evident in r tmax = 0.50. The overall study indicated that Magnesium hydroxide didn't affect the different physical parameters of plain tablet rather it in certain quantity while present in some batches assisted rapid disintegration and release profile of active content Diclofenac sodium. The DS-MH plain tablet to provide rapid disintegration, dissolution and absorption hence fastest antiinflammatory action with acid neutralizing benefits by MH, might be considered sincerely heumatoid arthritis and other inflammatory disorders have worldwide significance. Osteoarthritis causes up to sulphasalazine are major drugs for antiinflammatory and analgesic action. Costicosteroids are highly selective but have adverse; osteoporosis, fluid retention, dermis arthropaties effect and increases susceptibility to infection. Dyspepsia, gastric or peptic ulceration induced by NSAIDs limit their use. Thus searching for better GI-safe agents were continued and once succeeded to popular COX-2 inhibitors. Merck, the Rofecoxib manufacturer, in September 2004, withdrew the popular new anti-inflammatory drug Rofecoxib after a study that long-term use of these drugs doubled the risk of heart attack and stroke. Thus, 10% of adult population and inflammatory arthropathies about 2-3%. These diseases are responsible for up to 30% of physical disabilities and 60% of the burden of severe disabilities 1 . Rheumatic disease affects the people of all ages and ethnic groups. In UK, more than 40% over the year 65 have some kind of rheumatic disease, and 20 million people experience rheumatic complaints in each year. The NSAIDs, corticosteroids, opioiod analgesic, chloroquine, penicillamine, gold salt, R
http://www.banglajol.info/index.php/JBSP heumatoid arthritis and other inflammatory disorders have worldwide significance. Osteoarthritis causes up to sulphasalazine are major drugs for antiinflammatory and analgesic action. Costicosteroids are highly selective but have adverse; osteoporosis, fluid retention, dermis arthropaties effect and increases susceptibility to infection. Dyspepsia, gastric or peptic ulceration induced by NSAIDs limit their use. Thus searching for better GI-safe agents were continued and once succeeded to popular COX-2 inhibitors. Merck, the Rofecoxib manufacturer, in September 2004, withdrew the popular new anti-inflammatory drug Rofecoxib after a study that long-term use of these drugs doubled the risk of heart attack and stroke. Thus, 10% of adult population and inflammatory arthropathies about 2-3%. These diseases are responsible for up to 30% of physical disabilities and 60% of the burden of severe disabilities 1 . Rheumatic disease affects the people of all ages and ethnic groups. In UK, more than 40% over the year 65 have some kind of rheumatic disease, and 20 million people experience rheumatic complaints in each year. The NSAIDs, corticosteroids, opioiod analgesic, chloroquine, penicillamine, gold salt, exploration of safer anti-inflammatory drugs yet to be continued. Diclofenac sodium, one of the earliest NSAIDs member and first drug of phenyl acetic acid series has a wide range of therapeutic utility. It is the highly prescribed drug and has 30% prescription coverage from all NSAIDs market. It is used to treat osteoarthritis, rheumatic arthritis, chronic juvenile arthritis, low back pain, ankylosing spondylitis, post operative pain, renal pain, and pain in dental and other surgical operation. Diclofenac inhibits synthesis of prostaglandin by blocking the non-specific enzyme Cyclo-oxygenase (COX). Like other NSAID it has also GIT related adverse effects. However, bioavailability profile, antiinflammatory dose, therapeutic efficacy and relatively low ulcerogenic effect 2 To overcome the problems associated with NSAIDs related peptic ulcer and their life threatening complications prophylactic antiulcerant eg missoprostol, H 2 -receptor blockers, proton-pump inhibitors had been used since before 4 . Antisecretory dose of prostaglandin analogue such as misoprostol, abraprostil, enprostil and risoprostil have shown to be more effective than placebo but costly & less effective than H 2 -antagonist 5 . The antisecretory actions of Famotidine and Cimetidine have weak androgenic effect and hence Gynecomastia, impotence 6 lessened the interest for these agents. Proton pump inhibitors (Omeprazole, Lansoprazole, Pentoprazole, Rabeprazole or Esomeprazole) are being used but are not economic in treating NSAIDs associated hyperacidity. Besides the rebound hyper secretion of widely used omeprazole in about more than 82% in 15 days post treatment of H pylori negative patients and maximal basal acid output 28% 7 is one of the major objections. Antacids appear to be superior to placebo and equivalent to H 2 -receptor in releasing ulcers symptom 8, 9 . MH as antacid in diclofenac may be one of the best investigational agents in plain tablets.
Methods
For manufacturing of tablets the BP & USP specifications were followed. Ethical Drugs (Bangladesh) Ltd. provided the facilities to manufacture as many as the 20000 tablets of different formulation categories sufficient to conduct the study as required quality. Major machines, instruments and reagents used in the experiments are stated in Table: I and II. Preparation of simulated gastric fluid (SGF):
The SGF was prepared for pH 1.2, which was considered equivalent to the gastric environment. Sodium chloride of 2 grams was used against 7.0ml of 36.4% HCl and finally added sufficient distilled water to prepare 1000ml solution.
Determination of hardness, thickness, friability and weight variation: Crushing strength for hardness was the scale reading to break and was recorded for each time of six tablets and was used for the purpose of hardness test. The Vernier micrometer scale was used to determine the tablet thickness. Roche Friabilator was used to assess the effect of abrasion and shock by utilizing a plastic chamber at 25rpm and accelerated to 100rpm. The difference between the pre and post operation weight were determined after dedusting and the percent changes were recorded. All these operations were conducted as per British Pharmacopoeia 1988. Weight variation was done as per USP specification. Determination of disintegration time: disintegration method type II as per standard USP specification (six glass tube, 3
inches long 10mesh screen) in SGF of pH 1.2 at 37± 2 0C was used for this purpose. Construction of calibration curve: A calibration curve was constructed by plotting absorbance at 274nm against amount of diclofenac (reference standard) present in 0.1 (N) HCl solutions 10 . Determination of dissolution rate: USP dissolution calibration was done before starting the experiment. Dissolution test was done at temperature 37 0 C in Rotating Basket-1 in solution 0.1 N HCl, with 50rpm. The solutions were drawn 0 min 05 min, 10 min, 15min, 30 min, 60min, 75 min, 90min and 120min. The spectrophotometric readings were taken for solutions at 274nm through Quartz cell. The standard USP XXII/NFXVII apparatus was used for this operation. The dissolution media was used 900ml. The amount of diclofenac sodium was determined as per standard curve constructed.
Results
In the results, hardness, thickness, friability, weight variation, disintegration time and, dissolution rates are presented in Table - The dissolution rate of DS at different time period was determined and presented in Table - IV. 
Discussion
With the increment of any agent the average diameter (thickness) of tablet will be increased; thus average thickness increased 0.5mm, 1.4mm, 2.1mm and 2.4mm where MH increased in 200mg, 300mg, 350mg and 400mg in batches FO2, FO3, FO4 and FO5 respectively, it is rationale. A perfect positive correlation (r @1.0) between the changes of quantity of MH & average diameter (mm) of per tablet indicated no variation of excipients present in batch-tobatch preparation. With the addition of MH, hardness increased (table 3) that indicated the binder quality of MH.. A strong negative correlation (r= -0.9) exists between the friability and dissolution rate of this study explains that the higher the rate of friability, the lower is the rate of dissolution. A correlation exists between friability, hardness and in-vitro dissolution rate 11 . And release characteristics vary considerably among different manufacturers and that even identical formulation. MH might have a positive impact on hardness and in our study it is evident by r=0.49, calculated between the hardness and disintegration time ( Table-III Fig-2 , considering the addition of rationale quantity of Mg(OH) 2 ; the DT value (min) wouldn't be increased. Starch is typically used in a concentration 5% to 20% of the tablet weight and as a convention starch 5% as disintegrating agent is recommended; and If rapid disintegration is desired this amount may be increased 10 or 15% 13 . The starch contents in our test products were within the range of 10-14.6% in the four batches. As Mg (OH) 2 quantity increases the overall weight increases and thus, %age of starch is reduced (Table-II) . Among tablets in this study with 10-11% starch showed excellent DT profile, that are present in FO3, FO4, and FO5 batches. Moreover, size of the tablets exposed to GSF may have contributory role in reduction of disintegration time of the three batches as with increasing size the exposing surface area increases. From the data stated in Table- V it is evident that because of MH in any quantity, the dissolution rates were not affected rather then improvement (Figure-3 ). The rate of absorption and availability of many drugs that are administered orally in solid forms are the functions of their rate of dissolution in gastrointestinal fluids 14, 15 . The drug moieties, which are acidic in nature, absorb better in upper GIT 16 but one should not automatically expect a correlation between the disintegration time and dissolution rate and absorption through biological membrane. The researches conducted earlier demonstrated the possible variation of in-vitro dissolution of drug when composition of dosage form were altered 17, 18, 19 . This study showed diversified results but some were very much potential. It is established that the surface area of stomach is small compared to intestine (200m2), however some enteric coated preparation may resist dissolution in the intestine and very little portion of the drug is absorbed in gastric zone 20 . But release of active drug content at gastric zone instead of intestine will definitely provide additional area for absorption. Moreover, as of pH partition hypothesis 21 acidic drugs in acidic pH is favored the absorption; this is because of the fact that unionized portion of acidic drug will be predominating.
Diclofenac sodium is an acidic drug of pKa 4.0, and it is predicted that it will have favorable bioavailability profile if released at gastric zone. The standards limits of specification mentioned in this presentation indicate USP 22 .
Conclusion
Not all, some DS-MH preparations of this study were potential and indicated that MH was the key players in improving the disintegration time dissolution profile. The excellent DT profile of batch FO4 having 50mg DS with 350mg MH should be one of the best candidates for further study.
However the formulation approach 'Diclofenac sodium -Magnesium hydroxide' (DS-MH) plain tablet with the intention to early disintegration and dissolution of active Diclofenac sodium, in gastric zone to provide rapid absorption hence fastest anti-inflammatory action with acid neutralizing benefits by MH, might be considered sincerely. Further, bioequivalence studies may be necessary for commercial standpoint.
